Compare PZZA & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PZZA | TECX |
|---|---|---|
| Founded | 1984 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 640.7M | 618.9M |
| IPO Year | 1995 | 2018 |
| Metric | PZZA | TECX |
|---|---|---|
| Price | $19.70 | $23.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 9 |
| Target Price | $29.00 | ★ $76.63 |
| AVG Volume (30 Days) | ★ 1.4M | 233.3K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 7.09% | N/A |
| EPS Growth | N/A | ★ 40.70 |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $2,068,421,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $42.30 | ★ N/A |
| Revenue Growth | ★ 14.07 | N/A |
| 52 Week Low | $18.92 | $15.45 |
| 52 Week High | $55.74 | $39.53 |
| Indicator | PZZA | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 35.92 | 33.51 |
| Support Level | $19.31 | $20.52 |
| Resistance Level | $24.25 | $30.80 |
| Average True Range (ATR) | 0.62 | 1.39 |
| MACD | 0.18 | 0.11 |
| Stochastic Oscillator | 32.88 | 27.11 |
Papa John's International Inc operates and franchises pizza delivery and carryout restaurants and, in certain international markets, dine-in and delivery restaurants. It has four defined reportable segments: Domestic Company-owned restaurants, North America franchising, North America commissaries, and International. The company derives maximum revenue from North America commissaries segment. The North America commissaries segment consists of the operations of its regional dough production and product distribution centers in the United States and Canada and derives its revenues principally from the sale and distribution of food and paper products to Domestic Company-owned and franchised restaurants in the United States and Canada.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.